Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to take on the dominance of MSD’s Keytruda (pembrolizumab) in solid tumour ...

BMS and BioNTech will jointly develop and commercialise the asset that targets both PD-L1 and VEGF-A. ... will mean BMS and BioNTech jointly share development and manufacturing costs on a 50:50 ...

Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

Presence of KEVs, KEVs Linked to Ransomware, and Insecure Internet Exposure Found to be Pervasive Among BMS, BAS According to ...

Since the first-generation CAR-Ts reached the market several years ago, clinicians have become more adept at handling ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

However many shareholders have stakes in both Celgene and BMS, meaning that they stand to face less risk from the deal. Investors will get to vote on the acquisition in a special meeting scheduled ...

ASX health stocks fall in week ending June 20, 2025 as Morgans' analyst Scott Power says broader macro factors continue to drive markets.

Applied Systems announced last week that it would withdraw Epic from the UK after conducting a strategic review ...

Designed by Carbon Computers, the CyberT. is a BlackBerry-style handheld Linux computer equipped with a 4-inch panel built ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...